The Cannabis Investing Podcast · Seeking Alpha

De-risking psychedelics: Compass Pathways, Cybin and Atai

·48 min·13 clips

The conversation opens by noting there is more to say about psychedelics now than on earlier visits. It then moves straight into what has changed in the market and why the landscape feels more actionable. A major theme is that important catalysts are drawing closer. The guest says the field may be on the edge of its first FDA-approved psychedelic therapy by the end of the year, potentially. Regulatory progress is framed as the biggest development. That matters because it changes how investors think about the sector's credibility. The discussion does not treat approval as certain. Instead, it keeps stressing that timing is still uncertain and the space remains early. Compass Pathways, Cybin, and Atai come up as the names to watch. The reason is simple: they are leading the areas being discussed and have the clearest clinical and market relevance. The guest describes them as very risky even now. That risk is the usual early-stage biotech kind, especially the chance that late-stage data could bring surprises earlier studies did not show. The episode spends real time on that distinction. It is not about removing risk. It is about showing how the risk profile has shifted. One of the main claims is that the sector has been de-risked in the sense that regulators approving one of these medicines no longer sounds far-fetched. Another is that investors are more willing to fund the companies. The guest connects those two developments closely. If capital and regulation both move in a favorable direction, the market case changes a lot. The conversation also stays centered on specific lead programs rather than the sector as a whole. It notes that there are still no major red-flag safety signals in the most recent updates the guest has seen. That does not make the stocks safe. It does suggest the near-term story is more about execution than about surprise blowups. The episode also comes back to the idea that waiting may reduce upside. As more time passes and the market moves closer to the story, the pricing opportunity can narrow. That is the logic behind the basket approach discussed here. The names are treated as a group because the sector is still too volatile to call settled. Even so, the tone is not euphoric. It is steady, analytical, and grounded in the idea that better odds still come with real volatility. The result is a clear map of how psychedelic investing looks when the conversation is driven by data, regulation, and capital structure rather than sector hype alone.

As heard by us

A sober look at why psychedelics may be getting less risky without becoming safe.

The piece treats psychedelics less like a flashy trade and more like a question of de-risking: which names are starting to look sturdier as regulatory progress, clinical data, and investor appetite improve together.

Read the full review in PlayNext →

Why you'd press play

Hear how psychedelics are being de-risked as FDA approval edges closer.

Read the full recommendation in PlayNext →

Listen to the show on

Apple Podcasts Spotify

Play clips from this episode More from The Cannabis Investing Podcast